Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QL1206 in Chinese Postmenopausal Women With Osteoporosis
NCT04128163Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1206 in postmenopausal osteoporosis, sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
QL1206
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04128163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128163.